Related Experiment Videos
Heparin and secondary prevention of acute myocardial infarction
A Lotto1, A Colombo, G Talarico
1Cardiology Department, Ospedale Maggiore Policlinico, Milan, Italy.
Insights
Secondary prevention strategies after acute myocardial infarction (AMI) are crucial. Beta blockers, antiplatelets, and long-term heparin reduce mortality and reinfarction, though anticoagulants increase bleeding risk.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Patients surviving acute myocardial infarction (AMI) face significant risks of reinfarction, heart failure, and sudden death, contributing to high mortality.
- Early complications like angina or arrhythmias following AMI indicate a poorer prognosis.
- Secondary prevention of myocardial infarction and death has been a major focus of clinical research.
Purpose of the Study:
- To review the efficacy of various pharmacological interventions in the secondary prevention of clinical events after acute myocardial infarction.
- To evaluate the impact of beta blockers, antiplatelet agents, oral anticoagulants, and heparin on mortality and reinfarction rates.
Main Methods:
- Systematic review and meta-analysis of controlled randomized trials.
- Analysis of data from clinical trials investigating secondary prevention therapies post-AMI.
Main Results:
- Beta blockers are known to prevent sudden death with chronic administration post-AMI.
- Long-term antiplatelet treatment significantly reduces reinfarction and vascular death.
- Oral anticoagulants decrease reinfarction but increase bleeding risk; long-term heparin shows a significant reduction in recurrent AMI and a trend towards decreased mortality.
Conclusions:
- Effective secondary prevention strategies, including beta blockers, antiplatelets, and long-term heparin, are vital for improving outcomes after AMI.
- Risk-benefit assessment is necessary, particularly with oral anticoagulants due to increased haemorrhagic events.
Abstract:
Patients surviving acute myocardial infarction (AMI) may experience several clinical events (reinfarction, congestive heart failure, sudden death) still responsible for high mortality rates. AMI early complicated by residual angina, left ventricular dysfunction, or malignant arrhythmias has a worse prognosis. Secondary prevention of myocardial infarction and death has been the end point of many clinical trials in the past two decades. It is well known that beta blockers prevent sudden death if administered chronically after AMI. Meta-analysis of controlled randomized trials demonstrated a significant reduction in reinfarction and vascular death with long-term antiplatelet treatment. Oral anticoagulants prevent fatal and non-fatal reinfarction and show a trend towards lower mortality rates, though treated patients have a higher incidence of haemorrhagic events, particularly stroke. Early administration of heparin gave contradictory results on short-term prevention of myocardial infarction and death after AMI. Data on long-term heparin therapy point out a significant reduction in recurrent AMI and a trend towards a decrease in general mortality.